GET DAILY SIGNALSCardinal Health (CAH) Climbs +14% on Earnings Beat and Raised Guidance
Key Takeaways
- Cardinal Health (CAH) rose roughly 14% over the trailing 30 days, climbing from about $237.57 (October 9) to $271.72 (November 6) and reaching a fresh 52-week high.
- The move was driven by a beat-and-raise fiscal Q1 2027 report: adjusted EPS of $3.26 versus a ~$2.94 consensus, and revenue of $67.51 billion versus ~$66.6 billion.
- Management raised full-year fiscal 2027 adjusted EPS guidance to $12.80–$13.00 from $12.40–$12.60, implying roughly 17%–19% growth.
- Pharmaceutical and Specialty Solutions led the quarter, with segment profit up 17%, while the medical distribution segment saw profit decline 28% on flat revenue amid petroleum-cost pressure.
- Analysts responded with higher price targets after the release, and the CVS Health distribution agreement extension through mid-2032 added long-term revenue visibility.
- Get more detail on this ticker's Price Targets, Earnings, and Forecast to deepen your analysis.
- Explore Trending AI Robots to see how AI-driven trading systems are positioned across the market.
Cardinal Health (CAH) Business Overview
Cardinal Health, Inc. is a Dublin, Ohio-based healthcare services and pharmaceutical distribution company that connects manufacturers, pharmacies, hospitals, and other care providers. Its business is organized around three reportable segments: Pharmaceutical and Specialty Solutions, which accounted for roughly $62.6 billion of the quarter's $67.5 billion in revenue; Global Medical Products and Distribution (GMPD); and a group of higher-margin businesses including Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics. The United States represents the overwhelming majority of its sales.
The company operates a high-volume, low-margin distribution model, competing with peers such as McKesson and Cencora. Investors follow CAH for its scale, stable pharmaceutical demand, growing specialty drug exposure, and consistent earnings growth, which have helped the stock outperform the broader healthcare sector over the past year. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
CAH Stock Price Performance Over the Past 30 Days and Quarter
Over the last 30 days, CAH advanced roughly 14%, moving from about $237.57 on October 9 to $271.72 on November 6. The rally accelerated in the first week of November after the company's fiscal first-quarter earnings release, which pushed the stock to a new 52-week high.
The picture is similar over the last quarter, though the path was less linear. The stock entered the period near $236 in early August, pulled back to about $220 by late September, and then rebounded through October before surging after earnings. Measured over the trailing three months, CAH is up roughly 15%, reflecting steady underlying demand in pharmaceutical distribution and renewed momentum into the November report.
What Drove the Recent Move in CAH Shares
The primary catalyst was the fiscal Q1 2027 earnings release on November 5. Cardinal Health reported adjusted EPS of $3.26, up 28% year over year and well ahead of the ~$2.94 consensus, on revenue of $67.51 billion, up 5% year over year. Adjusted operating income rose 17% to about $1 billion, reflecting strong operating leverage in a thin-margin business. From what I see, this level of outperformance highlights the operating leverage in the model.
Management also raised its full-year outlook, lifting adjusted EPS guidance to $12.80–$13.00 from the prior $12.40–$12.60 and increasing Pharmaceutical and Specialty Solutions profit-growth guidance to 10%–12% from 8%–11%. Specialty pharmaceutical demand, strong generics performance, and GLP-1 medication volumes contributed to the pharmaceutical segment's 17% profit growth.
Supporting the move, several analysts raised price targets after the report, including RBC to $295, UBS to $310, and Mizuho to $290, all while maintaining bullish ratings. Earlier in the period, the company's announcement of a binding letter of intent to extend its pharmaceutical distribution agreement with CVS Health through June 30, 2032 added long-term contract visibility and contributed to positive sentiment.
Performance Drivers Over the Trailing Quarter
The quarterly trend reflects a broader multi-month narrative of consistent execution. Cardinal Health has now beaten consensus EPS estimates for four consecutive quarters, supported by pharmaceutical distribution scale, specialty drug growth, and favorable generics economics through its Red Oak Sourcing joint venture. The company has also reinforced its customer base, with contracts representing a large share of enterprise revenue renewed over the prior twelve months, including major pharmaceutical and medical distribution agreements.
Offsetting factors included margin pressure in the GMPD segment, where profit declined 28% on roughly flat revenue, partly due to elevated transportation and fuel costs tied to the ongoing Iran conflict and sustained high oil prices. Management kept GMPD full-year guidance unchanged but indicated results were tracking toward the lower end of the range. Despite this softness, stronger performance in the pharmaceutical and higher-margin "Other" segments, combined with share repurchases and dividend payments, supported the stock's overall advance during the quarter.
Key Areas to Watch for CAH Going Forward
Looking ahead, investors will likely focus on whether Cardinal Health can sustain its pharmaceutical segment momentum and deliver on the raised fiscal 2027 guidance. Key areas to monitor include the trajectory of GMPD margins and any easing of petroleum and transportation cost pressures, the integration and completion of the AdaptHealth Diabetes Health acquisition expected in the third quarter of fiscal 2027, and the progress of specialty and generic product launches in areas such as oncology, urology, and gastroenterology.
Regulatory developments, including potential changes to the 340B drug pricing program and Inflation Reduction Act-related pricing effects, also remain relevant to revenue and margin trends. Additionally, the company's long-term arrangements with major customers and the status of its Red Oak Sourcing relationship beyond 2029 could influence future earnings visibility. These factors, rather than short-term price movements, are likely to shape how the market assesses CAH over the coming quarters. I’m watching this closely as the guidance raises set a higher bar for execution.
AI Tools in My Research Process
One resource I turn to for additional perspective is Tickeron’s AI Trading Bots. The platform offers a range of automated strategies that can help compare signals across different market conditions and timeframes, providing a useful complement to traditional fundamental analysis when evaluating names like CAH.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
CAH's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CAH turned positive on November 04, 2026. Looking at past instances where CAH's MACD turned positive, the stock continued to rise in 34 of 42 cases over the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on CAH as a result. In 66 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
CAH moved above its 50-day moving average on October 08, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CAH crossed bullishly above the 50-day moving average on October 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +2.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where CAH advanced for three days, in 262 of 392 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Aroon Indicator entered an Uptrend today. In 188 of 310 cases where CAH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 58 cases where CAH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 48%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CAH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
CAH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 73, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 5 (best 1 - 100 worst), indicating outstanding price growth. CAH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-21.824) is normal, around the industry mean (14.423). CAH has a moderately high P/E Ratio (37.376) as compared to the industry average of (11.188). Projected Growth (PEG Ratio) (1.105) is also within normal values, averaging (2.016). Dividend Yield (0.008) settles around the average of (0.134) among similar stocks. P/S Ratio (0.217) is also within normal values, averaging (4.260).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of pharmaceuticals, medical, surgical and laboratory supplies as well as develops drug delivery systems
Industry MedicalDistributors
Advertisement